Results 111 to 120 of about 38,515 (217)

The wider implications of dactylitis beyond psoriatic arthritis. [PDF]

Commun Med (Lond)
Possemato N, Oliva M, Rai A, Girolimetto N, Caso F, Salvarani C, Marchesoni A, Helliwell PS.   +7 more
europepmc   +1 more source

Radiographic sacroiliitis progression in psoriatic arthritis. [PDF]

Rheumatology (Oxford)
Carrizo-Abarza V, Mehta P, Kharouf F, Gao S, Cook RJ, Gladman DD, Chandran V, Poddubnyy D.   +7 more
europepmc   +1 more source

Factors associated with drug adherence in psoriasis: a single‐center, retrospective, questionnaire‐based exploratory study in Bavaria

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Achieving sustained drug adherence in psoriasis remains challenging despite effective therapies. This exploratory study aims to investigate the care situation and factors associated with drug adherence in patients with moderate‐to‐severe psoriasis vulgaris (PsO). Patients and Methods A single‐center study was conducted
Negahr Jalili‐Tazeshahri, Gunnar Huppertz, Bernadett Kurz, Maria Isabel von Eichborn, Mark Berneburg, Tim Maisch, Dennis Niebel   +6 more
wiley   +1 more source

Skewed MHC Class I Peptide Presentation in Psoriatic Arthritis. [PDF]

Int J Mol Sci
Comdühr S, Sauer T, Deckert S, Pitann S, Schäfer M, Gemoll T, Arnold S, Klapa S, Riemekasten G, Thaçi D, Graßhoff H, Lamprecht P.   +11 more
europepmc   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Beyond Pain Intensity: The Relationship Between Pain Catastrophizing and Quality of Life in Psoriatic Arthritis. [PDF]

J Rheumatol
Chen K, Scher U, Scher JU, Haberman RH.
europepmc   +1 more source

Prevalence and Characteristics of North American Indigenous Inflammatory Skin Disease: A Systematic Scoping Review

International Journal of Dermatology, EarlyView.
This scoping review synthesizes evidence on atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa in North American Indigenous peoples across 49 studies and 63 clinical trials. Findings reveal consistently high disease burden in AD, marked underrepresentation in trials and guidelines, and five evidence‐based recommendations to advance ...
Rachel Asiniwasis, Jordanna Roesler, Amira Muftah, Aysha Lukmanji, McKenzie Van Eaton, Kavya Yatham, Erin Watson, Eric McMullen, Gregory Kost, Colton Jensen, Oluwatosin Odeshi, Anna Chacon, Dana Slape, Brittany Waller, Kelsey Hinther, Mamata Pandey, Carolyn Jack, Derek K. Chu   +17 more
wiley   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Metabolic Syndrome Is Independently Associated with Pain Severity in Psoriatic Arthritis. [PDF]

Biomedicines
Lamberti L, Currado D, Saracino F, Trunfio F, Frascà L, Marino A, Vomero M, Genovali I, Lorusso S, Corberi E, Padovan M, Giannini G, Kun L, Berardicurti O, Giacomelli R, Navarini L.   +15 more
europepmc   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source